Cargando…

Subcutaneous Interferon-β1a Does Not Increase the Risk of Stroke in Patients with Multiple Sclerosis: Analysis of Pooled Clinical Trials and Post-Marketing Surveillance

INTRODUCTION: Previous studies suggest that multiple sclerosis (MS) patients have a greater stroke risk than the general population but there is limited evidence of stroke risk in patients receiving disease-modifying treatment. We assessed stroke risk in MS patients treated with subcutaneous interfe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sabidó, Meritxell, Venkatesh, Saritha, Hayward, Brooke, Aldridge, Julie, Gillett, Alan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6224000/ https://www.ncbi.nlm.nih.gov/pubmed/30255416 http://dx.doi.org/10.1007/s12325-018-0790-1

Ejemplares similares

Reasons for discontinuation of subcutaneous interferon β-1a three times a week among patients with multiple sclerosis: a real-world cohort study
por: Sabidó-Espin, Meritxell, et al.
Publicado: (2017)

Effectiveness, Healthcare Resource Utilization and Adherence to Subcutaneous Interferon Beta-1a According to Age in Patients With Multiple Sclerosis: A Cohort Study Using a US Claims Database
por: Allignol, Arthur, et al.
Publicado: (2021)

Pregnancy outcomes in interferon-beta-exposed patients with multiple sclerosis: results from the European Interferon-beta Pregnancy Registry
por: Hellwig, Kerstin, et al.
Publicado: (2020)

A systematic review of relapse rates during pregnancy and postpartum in patients with relapsing multiple sclerosis
por: Hellwig, Kerstin, et al.
Publicado: (2021)

Transitioning from antenatal surveillance surveys to routine HIV testing: a turning point in the mother-to-child transmission prevention programme for HIV surveillance in Brazil
por: Pereira, Gerson Fernando Mendes, et al.
Publicado: (2017)

The association between exposure to interferon-beta during pregnancy and birth measurements in offspring of women with multiple sclerosis
por: Burkill, Sarah, et al.
Publicado: (2019)

Incidence of malignancy in multiple sclerosis: A cohort study in the Danish Multiple Sclerosis Registry
por: Nørgaard, Mette, et al.
Publicado: (2021)

A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis
por: Jaber, Amer, et al.
Publicado: (2008)

Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial
por: Dwyer, Michael G., et al.
Publicado: (2015)

Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart(®) in patients with multiple sclerosis
por: Edo Solsona, María Dolores, et al.
Publicado: (2017)

Outcomes of COVID-19 among patients treated with subcutaneous interferon beta-1a for multiple sclerosis
por: Freedman, Mark S., et al.
Publicado: (2021)

Interferon β-1a subcutaneously 3 times/week clinical outcome in relapsing multiple sclerosis in Finland
por: Järvinen, Elina, et al.
Publicado: (2019)

Efficacy and safety of subcutaneous interferon-β-1a in patients with a first demyelinating event and early multiple sclerosis
por: Freedman, Mark S
Publicado: (2014)

Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis
por: Kalincik, Tomas, et al.
Publicado: (2013)

A systematic review and meta-analyses of pregnancy and fetal outcomes in women with multiple sclerosis: a contribution from the IMI2 ConcePTION project
por: Lopez-Leon, Sandra, et al.
Publicado: (2020)

Severe Subcutaneous Calcification in an Interferon-β-treated MS Patient
por: Masuda, Hiroki, et al.
Publicado: (2017)

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
por: Xiong, Rui, et al.
Publicado: (2023)

Patient assessment of an electronic device for subcutaneous self-injection of interferon β-1a for multiple sclerosis: an observational study in the UK and Ireland
por: D’Arcy, Caroline, et al.
Publicado: (2012)

Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study
por: Freedman, Mark S., et al.
Publicado: (2014)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Beta-interferons in multiple sclerosis
por: Aggarwal, Sourabh, et al.
Publicado: (2010)

Interferon Treatment of Multiple Sclerosis
por: Alajbegovic, Azra, et al.
Publicado: (2012)

Antimicrobial resistance in Neisseria gonorrhoeae isolates from foreign-born population in the European Gonococcal Antimicrobial Surveillance Programme
por: Hernando Rovirola, Cristina, et al.
Publicado: (2020)

Effect of age on the effectiveness of the first-line standard of care treatment in patients with metastatic colorectal cancer: systematic review of observational studies
por: Dagher, Mohammed, et al.
Publicado: (2019)

ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study
por: Boeru, Gabriel, et al.
Publicado: (2013)

Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study
por: Zecca, Chiara, et al.
Publicado: (2017)

Interferon-gamma-induced local leukocytoclastic vasculitis at the subcutaneous injection site
por: Wang, Fang, et al.
Publicado: (2016)

Are we armed with the right data? Pooled individual data review of biomarkers in people with severe upper limb impairment after stroke
por: Hayward, Kathryn S, et al.
Publicado: (2016)

HIV Drug Resistance Surveillance Using Pooled Pyrosequencing
por: Ji, Hezhao, et al.
Publicado: (2010)

Pooled saliva samples for COVID-19 surveillance programme
por: Fogarty, Andrew, et al.
Publicado: (2020)

Pooled Testing for Expanding COVID-19 Mass Surveillance
por: Sunjaya, Angela Felicia, et al.
Publicado: (2020)

Evolution of the RebiSmart(®) Electromechanical Autoinjector to Improve Usability in Support of Adherence to Subcutaneous Interferon Beta-1a Therapy for People Living with Multiple Sclerosis
por: Lin, Yu-Ting, et al.
Publicado: (2023)

Erratum to "Are we armed with the right data? Pooled individual data review of biomarkers in people with severe upper limb impairment after stroke”
por: Hayward, Kathryn S., et al.
Publicado: (2017)

RARE-28. The use of subcutaneous interferon in patients with craniopharyngioma: an institutional retrospective review
por: Patil, Prabhumallikarjun, et al.
Publicado: (2022)

Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta‐1a
por: Battaglini, Marco, et al.
Publicado: (2022)

Pharmacokinetic Profile of Doxycycline in Koala Plasma after Weekly Subcutaneous Injections for the Treatment of Chlamydiosis
por: Chen, Chien-Jung, et al.
Publicado: (2022)

Surveillance of Legionella pneumophila: Detection in Public Swimming Pool Environment
por: Vukić Lušić, Darija, et al.
Publicado: (2022)

Metagenome Skimming of Insect Specimen Pools: Potential for Comparative Genomics
por: Linard, Benjamin, et al.
Publicado: (2015)

Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients
por: Allen-Philbey, Kimberley, et al.
Publicado: (2021)

The Role of Type 1 Interferon in Systemic Sclerosis
por: Wu, Minghua, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_0t8cteqpo6dhqeml05jpbaem5k